Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Breast Neoplasms

In brief

To determine the antitumor efficacy and the safety of SU-014813 at a dose of 100 mg orally once daily in patients with Metastatic Breast Cancer

Key facts

Study ID

NCT00322517

Run by

Pfizer

People needed

90

Starts

2006-04-01

Expected to finish

2009-07-01

Last updated by the study team

2011-05-17

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent.
• Must have received prior treatment with an anthracycline and a taxane either concurrently or sequentially in the adjuvant and/or advanced disease treatment settings. Patients may have received as many as 2 other chemotherapy regimens in the advanced disease setting. Patients whose tumors are Her-2-positive must have received prior trastuzumab therapy. Prior hormonal therapy or immunotherapy in the adjuvant and/or advanced/metastatic disease settings is permitted. Prior treatment with surgery, radiotherapy, chemoembolization therapy, or cryotherapy is allowed if these therapies did not affect the areas of measurable disease.

You may not qualify if…

• Prior treatment with >/= 3 regimens of chemotherapy in the metastatic disease setting beyond those containing anthracyclines and taxanes
• Uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months and should be asymptomatic

Where it is running

• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Pasadena, California, United States
• Pfizer Investigational Site — Santa Monica, California, United States
• Pfizer Investigational Site — Valancia, California, United States
• Pfizer Investigational Site — Corinth, Mississippi, United States
• Pfizer Investigational Site — Southaven, Mississippi, United States
• Pfizer Investigational Site — Memphis, Tennessee, United States
• Pfizer Investigational Site — Memphis, Tennessee, United States
• Pfizer Investigational Site — Hamburg, Germany
• Pfizer Investigational Site — Magdeburg, Germany
• Pfizer Investigational Site — Marburg, Germany
• Pfizer Investigational Site — Chieti Scalo, Italy
• Pfizer Investigational Site — Milan, Italy
• Pfizer Investigational Site — Mirano (VE), Italy
• Pfizer Investigational Site — Udine, Italy
• Pfizer Investigational Site — Amsterdam, Netherlands
• Pfizer Investigational Site — Rotterdam, Netherlands
• Pfizer Investigational Site — Manchester, M20 4bx, United Kingdom
• Pfizer Investigational Site — Sutton, Surrey, United Kingdom
• Pfizer Investigational Site — Edinburgh, United Kingdom
• Pfizer Investigational Site — London, United Kingdom
• Pfizer Investigational Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.